ICCC Immucell Corp

Price (delayed)

$11.42

Market cap

$103.82M

P/E Ratio

60.11

Dividend/share

N/A

EPS

$0.19

Enterprise value

$107.92M

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 21
Relative Profitability: Rel. Profitability: 46

ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense ®, providing ...

Highlights
Immucell's revenue has increased by 20% YoY and by 8% QoQ
ICCC's gross profit is up by 19% YoY and by 10% QoQ
ICCC's EPS has surged by 171% since the previous quarter but it is down by 32% year-on-year
The net income has surged by 139% since the previous quarter but it has declined by 19% year-on-year

Key stats

What are the main financial stats of ICCC

ICCC stock price

How has the Immucell stock price performed over time
Intraday
6.23%
1 week
11.74%
1 month
6.23%
1 year
111.48%
YTD
85.69%
QTD
16.53%

Financial performance

How have Immucell's revenue and profit performed over time
Revenue
$33.21M
Gross profit
$13.56M
Operating income
$4.8M
Net income
$1.88M
Gross margin
40.8%
Net margin
5.7%
The net income has surged by 139% since the previous quarter but it has declined by 19% year-on-year
Immucell's net margin has soared by 119% from the previous quarter but it has decreased by 32% YoY
The operating income has soared by 106% year-on-year and by 24% since the previous quarter
The operating margin has surged by 73% year-on-year and by 15% since the previous quarter

Price vs fundamentals

How does ICCC's price correlate with its fundamentals

Growth

What is Immucell's growth rate over time

Valuation

What is Immucell stock price valuation
P/E
60.11
P/B
3.16
P/S
3.12
EV/EBIT
56.09
EV/EBITDA
26.39
EV/Sales
3.25
ICCC's EPS has surged by 171% since the previous quarter but it is down by 32% year-on-year
The stock's P/B is 76% more than its 5-year quarterly average of 1.8 and 32% more than its last 4 quarters average of 2.4
The company's equity rose by 10% YoY and by 4.5% QoQ
The stock's P/S is 36% more than its 5-year quarterly average of 2.3 and 30% more than its last 4 quarters average of 2.4
Immucell's revenue has increased by 20% YoY and by 8% QoQ

Efficiency

How efficient is Immucell business performance
The company's return on equity has surged by 130% QoQ but it fell by 23% YoY
The ROA has soared by 128% since the previous quarter but it is down by 20% year-on-year
ICCC's ROIC has soared by 128% since the previous quarter but it is down by 11% year-on-year
ICCC's return on sales has surged by 107% since the previous quarter but it is down by 31% year-on-year

Dividends

What is ICCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICCC.

Financial health

How did Immucell financials performed over time
ICCC's quick ratio is up by 50% year-on-year but it is down by 9% since the previous quarter
Immucell's current ratio has increased by 10% YoY but it has decreased by 2.9% from the previous quarter
Immucell's debt is 63% less than its equity
The company's debt to equity fell by 20% YoY and by 8% QoQ
Immucell's debt has decreased by 12% YoY and by 3.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.